(LCI) $0.59--Phase 3 data within days ..there are around 4 million shares short so there could be a nice short squeeze on positive results Completed Dosing of Subjects in the Pivotal Biosimilar Insulin Glargine Clinical Trial, Top-line Results Anticipated by Year End